exhibit 10 ( vi ) appendix 4 this document is the english translation of the chinese version. in case of discrepancies between chinese and english versions, the chinese version shall prevail. oral antiviral therapy development and sales agreement party a : ainos inc. ( o. t. c. : aimd ) address : 8880 rio san diego drive, suite 800 san diego, ca 92108, u. s. a. party b : innopharmax ( 4172. t. w. o. ) address : 9f., no. 22, ln. 478, ruiguang rd., neihu dist., taipei city 11492, taiwan ( r. o. c. ) i. scope and purpose i. scope and purpose i. i. scope and purpose scope and purpose 1. party a and parity b agree to integrate existing technologies and drugs as combined therapy to cooperate on the following activities : conducting preclinical research, conducting clinical trials for regulatory approvals ; applying for regulatory approvals ; manufacturing of products ; cross - licensing and, under the principle of profit - sharing, developing disease indications caused by viral infection, including clinical trials for covid - 19 treatment, and obtaining regulatory approval in various countries around the world, and marketing the product upon product approval. 1. party a and parity b agree to integrate existing technologies and drugs as combined therapy to cooperate on the following activities : conducting preclinical research, conducting clinical trials for regulatory approvals ; applying for regulatory approvals ; manufacturing of products ; cross - licensing and, under the principle of profit - sharing, developing disease indications caused by viral infection, including clinical trials for covid - 19 treatment, and obtaining regulatory approval in various countries around the world, and marketing the product upon product approval. 1. 1. party a and parity b agree to integrate existing technologies and drugs as combined therapy to cooperate on the following activities : conducting preclinical research, conducting clinical trials for regulatory approvals ; applying for regulatory approvals ; manufacturing of products ; cross - licensing and, under the principle of profit - sharing, developing disease indications caused by viral infection, including clinical trials for covid - 19 treatment, and obtaining regulatory approval in various countries around the world, and marketing the product upon product approval. party a and parity b agree to integrate existing technologies and drugs as combined therapy to cooperate on the following activities